BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30760453)

  • 1. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation.
    Gagelmann N; Ditschkowski M; Bogdanov R; Bredin S; Robin M; Cassinat B; Shahswar R; Thol F; Heuser M; Socié G; Beelen D; Triviai I; Badbaran A; Kröger N
    Blood; 2019 May; 133(20):2233-2242. PubMed ID: 30760453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
    Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model.
    Hernández-Boluda JC; Pereira A; Alvarez-Larran A; Martín AA; Benzaquen A; Aguirre L; Mora E; González P; Mora J; Dorado N; Sampol A; García-Gutiérrez V; López-Godino O; Fox ML; Reguera JL; Pérez-Encinas M; Pascual MJ; Xicoy B; Parody R; González-Pinedo L; Español I; Avendaño A; Correa JG; Vallejo C; Jurado M; García-Cadenas I; Osorio S; Durán MA; Sánchez-Guijo F; Cervantes F; Piñana JL
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2237-2244. PubMed ID: 32717433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.
    Murata M; Suzuki R; Nishida T; Shirane S; Shimazu Y; Minami Y; Mori T; Doki N; Kanda Y; Uchida N; Tanaka M; Ishikawa J; Togitani K; Fukuda T; Ichinohe T; Atsuta Y; Nagamura-Inoue T; Kiyoi H
    Intern Med; 2020; 59(16):1947-1956. PubMed ID: 32801269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
    Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
    Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
    Lussana F; Rambaldi A; Finazzi MC; van Biezen A; Scholten M; Oldani E; Carobbio A; Iacobelli S; Finke J; Nagler A; Volin L; Lamy T; Arnold R; Mohty M; Michallet M; de Witte T; Olavarria E; Kröger N
    Haematologica; 2014 May; 99(5):916-21. PubMed ID: 24389309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.
    Kerbauy DM; Gooley TA; Sale GE; Flowers ME; Doney KC; Georges GE; Greene JE; Linenberger M; Petersdorf E; Sandmaier BM; Scott BL; Sorror M; Stirewalt DL; Stewart FM; Witherspoon RP; Storb R; Appelbaum FR; Deeg HJ
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):355-65. PubMed ID: 17317589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation.
    Kröger N; Panagiota V; Badbaran A; Zabelina T; Triviai I; Araujo Cruz MM; Shahswar R; Ayuk F; Gehlhaar M; Wolschke C; Bollin R; Walter C; Dugas M; Wiehlmann L; Lehmann U; Koenecke C; Chaturvedi A; Alchalby H; Stadler M; Eder M; Christopeit M; Göhring G; Koenigsmann M; Schlegelberger B; Kreipe HH; Ganser A; Stocking C; Fehse B; Thol F; Heuser M
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1095-1101. PubMed ID: 28389256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.
    Samuelson Bannow BT; Salit RB; Storer BE; Stevens EA; Wu D; Yeung C; Fang M; Petersdorf EW; Linenberger ML; Woo J; Sorror ML; Doney K; Sandmaier BM; Deeg HJ; Scott BL
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):386-392. PubMed ID: 28970176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
    Ali H; Aldoss I; Yang D; Mokhtari S; Khaled S; Aribi A; Afkhami M; Al Malki MM; Cao T; Mei M; O'Donnell M; Salhotra A; Pullarkat V; Yang L; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pillai R; Snyder D
    Blood Adv; 2019 Jan; 3(1):83-95. PubMed ID: 30622146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis.
    Tamari R; McLornan DP; Ahn KW; Estrada-Merly N; Hernández-Boluda JC; Giralt S; Palmer J; Gale RP; DeFilipp Z; Marks DI; van der Poel M; Verdonck LF; Battiwalla M; Diaz MA; Gupta V; Ali H; Litzow MR; Lazarus HM; Gergis U; Bashey A; Liesveld J; Hashmi S; Pu JJ; Beitinjaneh A; Bredeson C; Rizzieri D; Savani BN; Abid MB; Ganguly S; Agrawal V; Ulrike Bacher V; Wirk B; Jain T; Cutler C; Aljurf M; Kindwall-Keller T; Kharfan-Dabaja MA; Hildebrandt GC; Pawarode A; Solh MM; Yared JA; Grunwald MR; Nathan S; Nishihori T; Seo S; Scott BL; Nakamura R; Oran B; Czerw T; Yakoub-Agha I; Saber W
    Blood Adv; 2023 Aug; 7(15):3993-4002. PubMed ID: 37134306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.
    Mannina D; Gagelmann N; Badbaran A; Ditschkowski M; Bogdanov R; Robin M; Cassinat B; Heuser M; Shahswar R; Thol F; Beelen D; Kröger N
    Eur J Haematol; 2019 Dec; 103(6):552-557. PubMed ID: 31446640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
    Passamonti F; Giorgino T; Mora B; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Caramazza D; Merli M; Pietra D; Casalone R; Rotunno G; Barbui T; Cazzola M; Vannucchi AM
    Leukemia; 2017 Dec; 31(12):2726-2731. PubMed ID: 28561069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis.
    Anderson JE; Sale G; Appelbaum FR; Chauncey TR; Storb R
    Br J Haematol; 1997 Sep; 98(4):1010-6. PubMed ID: 9326205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.
    Kröger N; Zabelina T; Alchalby H; Stübig T; Wolschke C; Ayuk F; von Hünerbein N; Kvasnicka HM; Thiele J; Kreipe HH; Büsche G
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):812-5. PubMed ID: 24589549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Sequencing Improves DIPSS-Plus Prognostic Scoring in Myelofibrosis Patients Undergoing Allogeneic Transplantation.
    Stevens EA; Jenkins IC; Beppu LW; Zhang Q; Salit R; Loeb KR; Deeg HJ; Radich JP
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1371-1374. PubMed ID: 32194289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic.
    How J; Hobbs GS
    J Natl Compr Canc Netw; 2020 Sep; 18(9):1271-1278. PubMed ID: 32886896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?
    Salit RB; Deeg HJ
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):649-658. PubMed ID: 29128551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
    Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.